arrow_back Trending Legislation
Share share

Medicare: Enhanced Home Treatment Access for Neurological Conditions

This bill aims to expand Medicare coverage to include in-home administration of intravenous immune globulin (IVIG) for individuals with chronic neurological conditions like chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). This means patients with these conditions can receive essential treatment in the comfort of their own homes, potentially improving their quality of life and reducing the burden of clinic visits.
Key points
Starting January 1, 2026, Medicare will cover in-home IVIG administration for CIDP and MMN.
The bill allows for varying payment rates for IVIG administration based on the specific condition being treated, which may affect patient costs.
These changes are intended to improve access to treatment for patients with certain neurological diseases.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Medicare IVIG Access Enhancement Act of 2023
Print number: HR 5818
Sponsor: Rep. Smith, Adrian [R-NE-3]
Process start date: 2023-09-28
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Medicare: Enhanced Home Treatment Access for Neurological Conditions

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 5818.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-09-28.

What are the main provisions?

Key points include:

  • Starting January 1, 2026, Medicare will cover in-home IVIG administration for CIDP and MMN.
  • The bill allows for varying payment rates for IVIG administration based on the specific condition being treated, which may affect patient costs.
  • These changes are intended to improve access to treatment for patients with certain neurological diseases.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Smith, Adrian [R-NE-3].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Analysis and Potential Impact of HR 5818

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Benefits